Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TKT | P29401 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921224 | 0.87 | TDP1 (0.44) | TKTNOS1NOS2CYP11B1CYP11B2 | |
| SCHEMBL16390248 | 0.85 | NOS1 (0.42) | NOS1NOS2CHRNB2CHRNA4 | |
| SCHEMBL19909213 | 0.85 | TDP1 (0.52) | NOS1NOS2CYP3A4 | |
| SCHEMBL20937692 | 0.84 | TDP1 (0.50) | CYP3A4 | |
| SCHEMBL19909082 | 0.84 | TDP1 (0.50) | CYP3A4 | |
| SCHEMBL19909258 | 0.84 | TDP1 (0.50) | CYP3A4 | |
| SCHEMBL4410512 | 0.82 | NOS1 (0.42) | TKTNOS1NOS2CYP11B1CYP11B2 | |
| SCHEMBL30768308 | 0.81 | — | — | |
| SCHEMBL4783955 | 0.81 | — | — | |
| SCHEMBL6630716 | 0.80 | TKT (0.54) | TKTNOS1NOS2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833229-B2 | Labeling precursors with squaric acid coupling | SCV SPEZIAL-CHEMIKALIEN-VERTRIEBS GMBH (DE) | 2023-12-05 | — | — | US | disclosed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3008068-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2020-12-30 | — | — | EP | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| WO-2018128720-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | WO | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9637477-B2 | Therapeutic substituted pyrroles | ALLERGAN, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150336940-A1 | THERAPEUTIC SUBSTITUTED PYRROLES | ALLERGAN, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130190359-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20120165345-A1 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2010107742-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107739-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| US-4871848-A | OIL, GAS WELLS CORROSION INHIBITORS | THE DOW CHEMICAL COMPANY (US) | 1989-10-03 | — | — | US | disclosed |
| US-4740320-A | REACTION OF NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPONENT, KETONE OR ALDEHYDE, AMINE OR POLYAMINE | THE DOW CHEMICAL COMPANY (US) | 1988-04-26 | — | — | US | disclosed |
| US-4725373-A | CORROSION RESISTANCE FOR METAL TOOLS AND EQUIPMENT USED IN OIL AND GAS WELLS | THE DOW CHEMICAL COMPANY (US) | 1988-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190359-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | TKT 1595/4885NOS1 3141/4885NOS2 2996/4885 |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | TKT 3263/4885NOS1 3597/4885NOS2 2235/4885 |
| US-20150336940-A1 | THERAPEUTIC SUBSTITUTED PYRROLES | PTGS2, PTGES2, PTGIS | TKT 1882/4885NOS1 253/4885NOS2 40/4885 |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | TKT 1513/4885NOS1 2466/4885NOS2 2587/4885 |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | TKT 1595/4885NOS1 3141/4885NOS2 2996/4885 |
| US-20120165345-A1 | Heterocyclic compounds as pesticides | DDT, ACHE, PTMS | TKT 2342/4885NOS1 2996/4885NOS2 2951/4885 |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | TKT 351/4885NOS1 4476/4885NOS2 4350/4885 |
| US-11833229-B2 | Labeling precursors with squaric acid coupling | SCLY, SRRT, CS | TKT 65/4885NOS1 1328/4885NOS2 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.